Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155553 | 1.00 | FFAR1 (0.43) | FFAR1NR4A1NR4A2NR4A3ALOX5 | |
| SCHEMBL6156517 | 0.91 | FFAR1 (0.41) | FFAR1NR4A1NR4A2NR4A3ALOX5 | |
| SCHEMBL6156514 | 0.91 | FFAR1 (0.41) | FFAR1NR4A1NR4A2NR4A3ALOX5 | |
| SCHEMBL6880160 | 0.88 | FFAR1 (0.42) | FFAR1MRGPRX4ADAMTS4 | |
| SCHEMBL6880164 | 0.88 | FFAR1 (0.42) | FFAR1MRGPRX4ADAMTS4 | |
| SCHEMBL6155865 | 0.82 | FFAR1 (0.40) | FFAR1NR4A1NR4A2NR4A3ALOX5 | |
| SCHEMBL6155852 | 0.82 | VDR (0.49) | FFAR1ALOX5 | |
| SCHEMBL6155872 | 0.82 | VDR (0.49) | FFAR1ALOX5 | |
| SCHEMBL6881435 | 0.80 | FFAR1 (0.39) | FFAR1MRGPRX4ADAMTS4 | |
| SCHEMBL6881433 | 0.80 | FFAR1 (0.39) | FFAR1MRGPRX4ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |